Ratings Mankind Pharma Limited

Equities

MANKIND

INE634S01028

Market Closed - NSE India S.E. Other stock markets 07:43:53 2024-05-31 am EDT			5-day change	1st Jan Change
2,140 ^INR	+2.18%		+3.73%	+7.93%

May. 30	Advent International Receives 6-7 Bids for Bharat Serums	CI
May. 16	Transcript : Mankind Pharma Limited, Q4 2024 Earnings Call, May 16, 2024

Strengths

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 51% by 2026.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

With an expected P/E ratio at 46.8 and 38.83 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company appears highly valued given the size of its balance sheet.
The valuation of the company is particularly high given the cash flows generated by its activity.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
MANKIND PHARMA LIMITED	+7.93%	10.27B	-
ELI LILLY AND COMPANY	+40.73%	739B	C+
NOVO NORDISK A/S	+32.83%	598B	B
JOHNSON & JOHNSON	-6.30%	353B	C+
MERCK & CO., INC.	+15.15%	318B	B-
ABBVIE INC.	+4.05%	285B	C+
ASTRAZENECA PLC	+15.00%	240B	B+
ROCHE HOLDING AG	-5.52%	206B	A+
AMGEN INC.	+6.17%	164B	C+
PFIZER, INC.	-0.45%	162B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes